Рак Предстательной Железы: Радионуклидная Терапия С Лютецием-177 Псма
Keywords:
лютеций-177, рак предстательной железы, ПСМА, тераностика
Abstract
Простата специфический мембранный антиген (ПСМА) экспрессируется при неблагоприятном течении рака предстательной железы. ПСМА является маркером для новых методов тераностики. Тераностика – это сочетание двух слов: диагностика и лечение, которое одновременно диагностируется определенное заболевание, после этого исходя полученных результатов проводится лечение. Терапия изотопом Lu-177 ПСМА в основном используется у пациентов с распространённой формы рака предстательной железы. Цель обзорной статьи является анализировать и продемонстрировать результатов научных работ касающийся лечением с лютеций-177 ПСМА.
References
1. «Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer» Oliver Sartor, M.D., Johann de Bono, M.B., Ch.B., Ph.D., Kim N. Chi, M.D., Karim Fizazi, M.D., Ph.D., Ken Herrmann, M.D., Kambiz Rahbar, M.D., Scott T. Tagawa, M.D., Luke T. Nordquist, M.D., Nitin Vaishampayan, M.D., Ghassan El-Haddad, M.D., Chandler H. Park, M.D., Tomasz M. Beer, M.D., et al., for the VISION Investigators).
2. Lutetium-177-PSMA-617: A Vision of the Future. Elias Chandran, William D. Figg&Ravi Madan. Pages 186-190 | Received 08 Oct 2021, Accepted 27 Jan 2022, Published online: 27 Feb 2022).
3. IKNL. Cijfers over kanker. 2020. www.cijfersoverkanker.nl. Accessed 27 Mar 2020.
4. Kirby M, Hirst C, Crawford ED. Charaterising the castration-resistant prostate cancer population: a systematic review. Int J Clin Pract. 2011;65(11):1180–92.
5. Hotte SJ, Saad F. Current management of castrate-resistant prostate cancer. Curr Oncol. 2010;17(Suppl 2):S72–S9.
6. Bostwick DG, Pacelli A, Blute M, Roche P, Murphy GP. Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: a study of 184 cases. Cancer. 1998;82:2256–61.
7. Ghosh A, Heston WD. Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer. J Cell Biochem. 2004;91:528–39.
8. Mannweiler S, Amersdorfer P, Trajanoski S, Terrett JA, King D, Mehes G. Heterogeneity of prostate-specific membrane antigen (PSMA) expression in prostate carcinoma with distant metastasis. Pathol Oncol Res. 2009;15(2):167–72.
9. Ross JS, Sheehan CE, Fisher H. Correlation of primary tumor prostate-specific membrane antigen expression with disease recurrence in prostate cancer. Clin Cancer Res. 2003;9:6357–62.
10. ALSYMPCA Investigators, Parker C, Nilsson S, Heinrich D, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013;369:213–23.
11. Liu H, Moy P, Kim S, et al. Monoclonal antibodies to the extracellular domain of prostate-specific membrane antigen also react with tumor vascular endothelium. Cancer Res. 1997;57:3629–34.
12. Gallicchio R, Giacomobono S, Nardelli A, et al. Palliative treatment of bone metastases with samarium-153 EDTMP at onset of pain. J Bone Miner Metab. 2014;32:434–40.
13. Bander NH, Milowsky MI, Nanus DM, et al. Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer. J Clin Oncol. 2005;23:4591–601.
14. Tagawa ST, Milowsky MI, Morris M, et al. Phase II study of lutetium-177-labeled anti-prostatespecific membrane antigen monoclonal antibody J591 for metastatic castration-resistant prostate cancer. Clin Cancer Res. 2013;19:5182–91.
15. Kratochwil C, Giesel FL, Eder M, et al. 177Lu]Lutetium-labelled PSMA ligand-induced remission in a patient with metastatic prostate cancer. Eur J Nucl Med Mol Imaging. 2015;42(6):987–8.
16. Hillier SM, Maresca KP, Femia FJ, et al. Preclinical evaluation of novel glutamate-urea-lysine analogues that target prostate-specific membrane antigen as molecular imaging pharmaceuticals for prostate cancer. Cancer Res. 2009;69(17):6932–40.
2. Lutetium-177-PSMA-617: A Vision of the Future. Elias Chandran, William D. Figg&Ravi Madan. Pages 186-190 | Received 08 Oct 2021, Accepted 27 Jan 2022, Published online: 27 Feb 2022).
3. IKNL. Cijfers over kanker. 2020. www.cijfersoverkanker.nl. Accessed 27 Mar 2020.
4. Kirby M, Hirst C, Crawford ED. Charaterising the castration-resistant prostate cancer population: a systematic review. Int J Clin Pract. 2011;65(11):1180–92.
5. Hotte SJ, Saad F. Current management of castrate-resistant prostate cancer. Curr Oncol. 2010;17(Suppl 2):S72–S9.
6. Bostwick DG, Pacelli A, Blute M, Roche P, Murphy GP. Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: a study of 184 cases. Cancer. 1998;82:2256–61.
7. Ghosh A, Heston WD. Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer. J Cell Biochem. 2004;91:528–39.
8. Mannweiler S, Amersdorfer P, Trajanoski S, Terrett JA, King D, Mehes G. Heterogeneity of prostate-specific membrane antigen (PSMA) expression in prostate carcinoma with distant metastasis. Pathol Oncol Res. 2009;15(2):167–72.
9. Ross JS, Sheehan CE, Fisher H. Correlation of primary tumor prostate-specific membrane antigen expression with disease recurrence in prostate cancer. Clin Cancer Res. 2003;9:6357–62.
10. ALSYMPCA Investigators, Parker C, Nilsson S, Heinrich D, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013;369:213–23.
11. Liu H, Moy P, Kim S, et al. Monoclonal antibodies to the extracellular domain of prostate-specific membrane antigen also react with tumor vascular endothelium. Cancer Res. 1997;57:3629–34.
12. Gallicchio R, Giacomobono S, Nardelli A, et al. Palliative treatment of bone metastases with samarium-153 EDTMP at onset of pain. J Bone Miner Metab. 2014;32:434–40.
13. Bander NH, Milowsky MI, Nanus DM, et al. Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer. J Clin Oncol. 2005;23:4591–601.
14. Tagawa ST, Milowsky MI, Morris M, et al. Phase II study of lutetium-177-labeled anti-prostatespecific membrane antigen monoclonal antibody J591 for metastatic castration-resistant prostate cancer. Clin Cancer Res. 2013;19:5182–91.
15. Kratochwil C, Giesel FL, Eder M, et al. 177Lu]Lutetium-labelled PSMA ligand-induced remission in a patient with metastatic prostate cancer. Eur J Nucl Med Mol Imaging. 2015;42(6):987–8.
16. Hillier SM, Maresca KP, Femia FJ, et al. Preclinical evaluation of novel glutamate-urea-lysine analogues that target prostate-specific membrane antigen as molecular imaging pharmaceuticals for prostate cancer. Cancer Res. 2009;69(17):6932–40.
Published
2022-07-27
How to Cite
Нигматович, Т. М., Арифович , З. Д., & Бахтиёрович, Н. Д. (2022). Рак Предстательной Железы: Радионуклидная Терапия С Лютецием-177 Псма. Central Asian Journal of Medical and Natural Science, 3(4), 146-153. https://doi.org/10.17605/cajmns.v3i4.988
Issue
Section
Articles
